Stock listing
NASDAQ:VIVS VivoSim Labs, Inc. Stock
Home listing (NASDAQ) of VivoSim Labs, Inc.
Follow VivoSim Labs, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:VIVS
$0.261 USD -0.031 (-10.5%)
Close on Nov 20, 2026
- Day range
- $0.244 – $0.381 USDNov 20, 2026
- Volume
- 149.2M sharesNov 20, 2026
- Market cap
- $5.29M USDAt the close on Nov 20, 2026 · price × 20.28M shares outstanding
- 52-week range
- $0.118 – $3.400 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.37M USDMedian day 560,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:VIVS · Home | $0.261 USD | -0.031 (-10.5%) | 149,183,534 | $0.280 | $0.381 | $0.244 | $0.292 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:VIVS · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.261 | -0.031 | -10.5% | $0.280 | $0.381 | $0.244 | 149,183,534 | |
| $0.292 | +0.171 | +142.9% | $0.195 | $0.323 | $0.169 | 815,947,375 | |
| $0.120 | 0.000 | -0.1% | $0.120 | $0.126 | $0.119 | 264,657 | |
| $0.120 | -0.004 | -2.9% | $0.123 | $0.126 | $0.118 | 249,571 | |
| $0.124 | -0.006 | -4.8% | $0.131 | $0.131 | $0.122 | 231,880 | |
| $0.130 | -0.010 | -7.1% | $0.140 | $0.140 | $0.130 | 451,100 | |
| $0.140 | -0.010 | -6.7% | $0.160 | $0.160 | $0.130 | 1,614,900 | |
| $0.150 | +0.020 | +15.4% | $0.130 | $0.180 | $0.130 | 6,966,800 | |
| $0.130 | -0.010 | -7.1% | $0.150 | $0.150 | $0.120 | 561,400 | |
| $0.140 | 0.000 | 0.0% | $0.140 | $0.150 | $0.140 | 369,300 | |
| $0.140 | 0.000 | 0.0% | $0.140 | $0.140 | $0.140 | 160,600 | |
| $0.140 | -0.010 | -6.7% | $0.150 | $0.150 | $0.140 | 527,300 | |
| $0.150 | +0.010 | +7.1% | $0.160 | $0.160 | $0.140 | 540,900 | |
| $0.140 | -0.010 | -6.7% | $0.150 | $0.150 | $0.140 | 1,513,500 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.160 | $0.150 | 531,800 | |
| $0.150 | -0.010 | -6.3% | $0.150 | $0.160 | $0.140 | 755,800 | |
| $0.160 | +0.010 | +6.7% | $0.150 | $0.170 | $0.150 | 2,566,200 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.150 | $0.140 | 320,100 | |
| $0.150 | 0.000 | 0.0% | $0.160 | $0.160 | $0.150 | 476,200 | |
| $0.150 | 0.000 | 0.0% | $0.150 | $0.160 | $0.140 | 566,900 | |
| $0.150 | -0.010 | -6.3% | $0.150 | $0.160 | $0.140 | 745,500 | |
| $0.160 | -0.020 | -11.1% | $0.180 | $0.180 | $0.150 | 2,658,100 | |
| $0.180 | +0.010 | +5.9% | $0.160 | $0.180 | $0.160 | 2,647,900 | |
| $0.170 | +0.010 | +6.3% | $0.160 | $0.180 | $0.160 | 692,300 | |
| $0.160 | 0.000 | 0.0% | $0.160 | $0.160 | $0.160 | 357,200 | |
| $0.160 | -0.010 | -5.9% | $0.160 | $0.170 | $0.150 | 822,900 | |
| $0.170 | +0.010 | +6.3% | $0.160 | $0.190 | $0.150 | 3,512,500 | |
| $0.160 | -0.010 | -5.9% | $0.170 | $0.170 | $0.160 | 356,600 | |
| $0.170 | 0.000 | 0.0% | $0.180 | $0.180 | $0.170 | 181,000 | |
| $0.170 | -0.010 | -5.6% | $0.180 | $0.180 | $0.170 | 1,096,800 | |
| $0.180 | 0.000 | 0.0% | $0.180 | $0.180 | $0.170 | 332,200 | |
| $0.180 | -0.010 | -5.3% | $0.190 | $0.190 | $0.170 | 872,700 | |
| $0.190 | -0.010 | -5.0% | $0.200 | $0.210 | $0.190 | 881,200 | |
| $0.200 | -0.010 | -4.8% | $0.210 | $0.210 | $0.200 | 374,900 | |
| $0.210 | +0.010 | +5.0% | $0.200 | $0.210 | $0.190 | 444,300 | |
| $0.200 | -0.010 | -4.8% | $0.210 | $0.210 | $0.190 | 804,500 | |
| $0.210 | 0.000 | 0.0% | $0.210 | $0.220 | $0.210 | 185,300 | |
| $0.210 | +0.010 | +5.0% | $0.200 | $0.220 | $0.200 | 558,100 | |
| $0.200 | -0.020 | -9.1% | $0.230 | $0.230 | $0.200 | 647,800 | |
| $0.220 | 0.000 | 0.0% | $0.230 | $0.230 | $0.220 | 423,900 | |
| $0.220 | -0.010 | -4.3% | $0.230 | $0.230 | $0.220 | 253,000 | |
| $0.230 | 0.000 | 0.0% | $0.230 | $0.230 | $0.220 | 559,000 | |
| $0.230 | -0.010 | -4.2% | $0.240 | $0.240 | $0.220 | 615,400 | |
| $0.240 | -0.010 | -4.0% | $0.250 | $0.260 | $0.230 | 1,242,600 | |
| $0.250 | +0.020 | +8.7% | $0.230 | $0.260 | $0.220 | 1,451,300 | |
| $0.230 | -0.030 | -11.5% | $0.260 | $0.260 | $0.220 | 1,568,400 | |
| $0.260 | 0.000 | 0.0% | $0.270 | $0.270 | $0.260 | 595,100 | |
| $0.260 | -0.010 | -3.7% | $0.270 | $0.270 | $0.250 | 6,387,800 | |
| $0.270 | -0.010 | -3.6% | $0.280 | $0.280 | $0.270 | 304,700 | |
| $0.280 | 0.000 | 0.0% | $0.290 | $0.290 | $0.270 | 389,100 | |
| $0.280 | -0.020 | -6.7% | $0.300 | $0.300 | $0.280 | 419,900 | |
| $0.300 | +0.020 | +7.1% | $0.280 | $0.300 | $0.270 | 1,401,200 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.290 | $0.270 | 398,200 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.290 | $0.270 | 696,900 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.280 | 267,900 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.270 | 606,300 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.270 | 386,600 | |
| $0.280 | -0.010 | -3.4% | $0.300 | $0.300 | $0.270 | 366,400 | |
| $0.290 | 0.000 | 0.0% | $0.290 | $0.290 | $0.280 | 358,800 | |
| $0.290 | 0.000 | 0.0% | $0.290 | $0.300 | $0.290 | 230,800 | |
| $0.290 | 0.000 | 0.0% | $0.290 | $0.300 | $0.280 | 333,000 | |
| $0.290 | -0.002 | -0.5% | $0.290 | $0.300 | $0.280 | 283,100 | |
| $0.292 | 0.000 | -0.1% | $0.287 | $0.300 | $0.281 | 647,948 | |
| $0.292 | +0.002 | +0.7% | $0.284 | $0.304 | $0.276 | 969,780 | |
| $0.290 | +0.010 | +3.6% | $0.280 | $0.290 | $0.270 | 715,800 | |
| $0.280 | 0.000 | 0.0% | $0.280 | $0.280 | $0.270 | 803,200 |
Splits
2 splits since 2020 · NASDAQ:VIVS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-12 | Consolidation | |
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:VIVS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
Latest deck · 2026
Investor Presentation (2026)
Investor deck · 22 slides
Latest news
VivoSim Labs Signs Seven-Figure Agreement with a Top-10 Global Pharmaceutical Company; Expects to Exceed Its 500%+ Revenue Growth Guidance for Fiscal 2027
Nov 19, 2026
Closed $0.292 (+142.9%) on Nov 19, 2026
VivoSim Labs to Showcase Breakthrough Multiparametric NAMkind™ Liver and Intestine Data at the 2026 American College of Toxicology (ACT) Annual Meeting
Nov 16, 2026
Closed $0.124 (-4.8%) on Nov 16, 2026
VivoSim Labs to Showcase Multiparametric Human 3D Tissue Safety Data at the American College of Toxicology (ACT) 47th Annual Meeting
Nov 10, 2026
Closed $0.13 (-7.1%) on Nov 10, 2026
VivoSim Labs and Chemveda Life Sciences Join Forces to Put AI-Designed Drug Candidates to the Human Test
Nov 3, 2026
Closed $0.14 (-6.7%) on Nov 3, 2026
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
Oct 21, 2026
Closed $0.18 (+5.9%) on Oct 21, 2026
VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
Oct 7, 2026
Closed $0.19 (-5.0%) on Oct 7, 2026
VivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
Sep 16, 2026
Closed $0.26 (-3.7%) on Sep 16, 2026
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
Sep 1, 2026
Closed $0.28 (-3.4%) on Sep 1, 2026
VivoSim Provides Financial and Listing Compliance Update
Aug 6, 2026
Closed $0.33 (-8.3%) on Aug 6, 2026
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
Jul 21, 2026
Closed $0.45 (-10.0%) on Jul 21, 2026
VivoSim Labs, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 23 in the last 12 months · 69 in all · newest Nov 19, 2026 · oldest 2019
- Decks
- 1 deck · latest 2026
Where VivoSim Labs, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:VIVS · Home listing · This page | NASDAQ | United States | USD |
| Munich:4OR | Munich | Germany | EUR |
| LSE:0R02 | LSE | United Kingdom | USD |
| gettex:4OR | gettex | Germany | EUR |
| BOATS:VIVS | BOATS | United States | USD |
| Frankfurt:4OR | Frankfurt | Germany | EUR |
| LS Exchange:A41083 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A41083 | Lang & Schwarz | Germany | EUR |
| Stuttgart:4OR | Stuttgart | Germany | EUR |
Valuation
EV/sales −20.5× against a median of 1.6×: the lowest of 10 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$2.76M USD
- P/E
- Loss
- EV/sales
- −20.5×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.91
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| VivoSim Labs, Inc. · NASDAQ:VIVS | US$5.29M | −US$2.76M | n/a | −20.5× | n/a | 0.7× | n/a | 0.1× | 1.91 |
| iXensor Co., Ltd. · TPEX:6734 | US$6.01M | US$5.63M | n/a | 6.9× | n/a | 23.1× | −174.7% | 0.9× | n/a |
| Cizzle Biotechnology Holdings PLC · LSE:CIZ | US$5.70M | US$5.59M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| AcouSort AB · OMXSTO:ACOU | US$5.69M | US$4.76M | n/a | 6.1× | n/a | 5.9× | −140.8% | 0.0× | n/a |
| GENinCode PLC · LSE:GENI | US$5.42M | US$2.86M | n/a | 0.7× | n/a | 2.0× | −185.5% | 0.1× | n/a |
| Nanologica AB · OMXSTO:NICA | US$5.29M | US$8.67M | 2.9× | 1.6× | n/a | 0.3× | 34.9% | 0.3× | n/a |
| Biomerica, Inc. · NASDAQ:BMRA | US$4.97M | US$2.23M | n/a | 0.5× | n/a | 1.4× | −115.5% | 0.0× | 0.71 |
| VolitionRx Limited · AMEX:VNRX | US$4.87M | US$9.19M | n/a | 2.7× | n/a | n/a | −698.5% | n/a | 1.52 |
| Boule Diagnostics AB · OMXSTO:BOUL | US$4.84M | US$24.70M | n/a | 0.6× | n/a | 0.3× | −4.0% | 1.3× | n/a |
| BioInfra Co.,Ltd. · KRX:199730 | US$4.75M | −US$509,202 | n/a | −0.0× | n/a | 0.5× | −32.3% | 0.0× | n/a |
| Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO | US$4.74M | US$4.74M | n/a | 312× | n/a | 0.8× | n/a | 0.0× | 2.07 |
| Median of the others | US$5.13M | US$5.18M | 2.9× | 1.6× | 1.1× | −128.1% | 0.0× | 1.52 |
Team and board
Officers
| Officer | Role |
|---|---|
| Doug Cohen | Chief Executive Officer |
| Norman Staskey | Chief Financial Officer |
| Amar A. Sethi | Chief Science Officer |
| Keith Murphy | Executive Chairman |
| Tony Lialin | Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Keith Murphy | Executive Chairman |
| Adam K. Stern | Director |
| Alison Milhous | Director |
| David Gobel | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 12, 2026 | −13.3% |
| Q1 2027 | Aug 12, 2026 | −5.7% |
| Q4 2026 | Jun 25, 2026 | −5.5% |
| Q3 2026 | Feb 27, 2026 | −1.4% |
| Q2 2026 | Nov 6, 2025 | −4.4% |
| Q1 2026 | Aug 12, 2025 | +4.5% |
| Q4 2025 | May 22, 2025 | +1.5% |
| Q3 2025 | Feb 19, 2025 · Before open | 0.0% |
| Q2 2025 | Nov 8, 2024 · After close | 0.0% |
| Q1 2025 | Aug 5, 2024 · After close | 0.0% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | May 10, 2024 · After close | +3.3% |
| Q3 2024 | Feb 8, 2024 · After close | −10.0% |
| Q2 2024 | Nov 9, 2023 · After close | −7.5% |
| Q1 2024 | Aug 10, 2023 | −0.6% |
| Q4 2023 | May 25, 2023 | +7.9% |
| Q3 2023 | Feb 9, 2023 | +6.7% |
| Q2 2023 | Nov 10, 2022 | +7.3% |
| Q1 2023 | Aug 11, 2022 | −2.1% |
| Q4 2022 | May 26, 2022 | +1.7% |
| Q3 2022 | Feb 8, 2022 | −7.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (2026) | Investor deck | 22 slides | 2026 |
Financings
| Raise | Date |
|---|---|
| Private placement of pre-funded warrants and common warrants Closed: US$4M raised · US$0.85 a share · Warrants at US$0.85 for 60 months · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Working capital and general corporate purposes | Aug 6, 2026 |
| Warrant exercise of common stock issued on warrant exercises and at-the-market sales Closed: US$2.3M raised | Mar 6, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 131.0K | 144.0K | 109.0K | 370.0K | 1.50M | 0 | 2.20M | 3.09M | 4.60M | 4.23M |
| Cost of revenue | 0 | 5.00K | 0 | 0 | 300.0K | 500.0K | 1.00M | 956.0K | ||
| Gross profit | 131.0K | 139.0K | 109.0K | 370.0K | 1.50M | 0 | 1.87M | 2.61M | 3.57M | 3.27M |
| Research and development | 4.19M | 5.03M | 5.50M | 8.88M | 3.32M | 1.10M | 5.28M | 14.8M | 18.0M | 19.5M |
| Selling, general and administrative | 7.43M | 7.73M | 9.70M | 9.22M | 9.66M | 15.7M | 18.1M | 15.1M | 20.9M | 22.3M |
| Operating income | -11.5M | -12.6M | -15.1M | -17.7M | -11.5M | -16.8M | -21.5M | -27.3M | -35.3M | -38.6M |
| Depreciation and amortization | 215.0K | 266.0K | 280.0K | 293.0K | 142.0K | 41.0K | 1.14M | 980.0K | 1.27M | 1.15M |
| EBITDA | -11.3M | -12.3M | -14.8M | -17.4M | -11.3M | -16.8M | -20.3M | -26.3M | -34.0M | -37.4M |
| Interest expense | 12.0K | 10.0K | 0 | 0 | ||||||
| Income before tax | -13.8M | -2.49M | -14.7M | -17.3M | -11.4M | -16.8M | -18.7M | -26.6M | -34.8M | -38.4M |
| Income tax | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K | 2.00K | 3.00K | 2.00K | 23.0K |
| Net income | -13.8M | -2.49M | -14.7M | -17.3M | -11.4M | -16.8M | -18.7M | -26.6M | -34.8M | -38.4M |
| Earnings per share, basic | -5.35 | -1.70 | -19.25 | -1.98 | -1.32 | -2.44 | -2.80 | -0.23 | -0.32 | -0.39 |
| Earnings per share, diluted | -5.35 | -1.70 | -19.25 | -1.98 | -1.32 | -2.44 | -2.80 | -0.23 | -0.32 | -0.39 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.02M | 11.3M | 2.90M | 15.3M | 28.7M | 37.4M | 27.4M | 36.5M | 43.7M | 62.8M |
| Short-term investments | 0 | 706.0K | 0 | |||||||
| Receivables | 32.0K | 30.0K | 33.0K | 152.0K | 0 | 0 | 111.0K | 503.0K | 883.0K | 647.0K |
| Inventory | 0 | 0 | 297.0K | 0 | 0 | 490.0K | 842.0K | 550.0K | ||
| Current assets | 6.63M | 12.1M | 3.94M | 17.0M | 29.5M | 38.4M | 28.3M | 38.6M | 46.8M | 65.1M |
| Property, plant and equipment | 206.0K | 419.0K | 669.0K | 902.0K | 662.0K | 381.0K | 0 | 1.83M | 2.79M | 3.84M |
| Total assets | 7.39M | 14.7M | 6.35M | 20.3M | 33.3M | 39.9M | 28.4M | 40.6M | 49.8M | 69.2M |
| Accounts payable | 1.02M | 1.64M | 627.0K | 331.0K | 415.0K | 281.0K | 720.0K | 628.0K | 464.0K | 1.17M |
| Current liabilities | 2.79M | 3.74M | 1.86M | 3.67M | 1.38M | 721.0K | 1.81M | 3.74M | 4.66M | 6.01M |
| Total debt | 447.0K | 942.0K | 1.39M | 1.80M | 2.18M | |||||
| Total liabilities | 8.48M | 4.16M | 2.75M | 4.98M | 3.09M | 721.0K | 1.81M | 4.33M | 5.24M | 6.82M |
| Shareholders' equity | -1.10M | 10.5M | 3.60M | 15.3M | 30.2M | 39.2M | 26.6M | 36.3M | 44.6M | 62.4M |
| Shares outstanding | 2.89M | 1.90M | 839.8K | 8.72M | 8.71M | 8.67M | 6.53M | 124.0M | 111.0M | 104.6M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.8M | -9.46M | -14.7M | -12.4M | -8.45M | -13.3M | -14.9M | -20.4M | -28.9M | -29.2M |
| Capital spending | 0 | -13.0K | -42.0K | -396.0K | -409.0K | -405.0K | 0 | -79.0K | -226.0K | -1.35M |
| Free cash flow | -10.8M | -9.47M | -14.7M | -12.8M | -8.86M | -13.7M | -14.9M | -20.5M | -29.1M | -30.5M |
| Cash from investing | 94.0K | 9.03M | 816.0K | -966.0K | -409.0K | -393.0K | 747.0K | -76.0K | -292.0K | -1.39M |
| Cash from financing | 4.45M | 8.85M | 1.44M | 0 | 205.0K | 23.8M | 4.93M | 13.2M | 10.1M | 31.2M |
| Share buybacks | 0 | -1.00K | 0 | |||||||
| Change in cash | -6.29M | 8.41M | -12.4M | -13.4M | -8.66M | 10.1M | -9.20M | -7.30M | -19.0M | 660.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Oct 16, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 6, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Aug 21, 2026 | Annual report | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| DEF 14A · Proxy statement | Aug 21, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 17, 2026 | Big-stake notice | SEC |
| PRER14A | Aug 13, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
All 820 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| EFFECT · Notice that a registration is effective | Aug 11, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Aug 10, 2026 | Meeting notice | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| S-1 · Registration statement | Jul 31, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 30, 2026 | Current report | SEC |
| 8-K · Current report | Jul 24, 2026 | Current report | SEC |
| 8-K · Current report | Jul 17, 2026 | Material contract | SEC |
| 10-K · Annual report | Jul 14, 2026 | Annual report | SEC |
| NT 10-K · Late filing notice | Jun 29, 2026 | Explanation request | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 3, 2026 | Material contract | SEC |
| 424B4 · Prospectus | Apr 2, 2026 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 1, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 31, 2026 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 31, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 30, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 30, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2026 | Other filings | SEC |
| S-1 · Registration statement | Mar 27, 2026 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 13, 2026 | Other filings | SEC |
| DRS · Draft registration statement | Mar 9, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Feb 11, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Nov 6, 2025 | Annual report | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Nov 3, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 3, 2025 | Meeting notice | SEC |
| RW · Request to withdraw a registration | Sep 25, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Aug 28, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 21, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 21, 2025 | Insider trade | SEC |
| 8-K · Current report | Aug 14, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jul 29, 2025 | Annual report | SEC |
| 10-K · Annual report | Jun 5, 2025 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 6, 2025 | Current report | SEC |
| 8-K · Current report | Apr 24, 2025 | Current report | SEC |
| 8-K · Current report | Apr 23, 2025 | Current report | SEC |
| 424B5 · Prospectus | Apr 11, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 2, 2025 | Results | SEC |
| 8-K · Current report | Mar 27, 2025 | Current report | SEC |
| 8-K · Current report | Mar 26, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Mar 21, 2025 | Current report | SEC |
| 8-K · Current report | Mar 19, 2025 | Current report | SEC |
| 8-K · Current report | Mar 6, 2025 | Current report | SEC |
| 424B5 · Prospectus | Feb 26, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 25, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | Feb 19, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| NT 10-Q · Late filing notice | Feb 14, 2025 | Explanation request | SEC |
| 8-K · Current report | Jan 17, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Jan 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 31, 2024 | Management or board change | SEC |
| 8-K · Current report | Nov 22, 2024 | Management or board change | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 8, 2024 | Quarterly report | SEC |
| S-1 · Registration statement | Oct 25, 2024 | Offer document | SEC |
| ARS · Annual report to shareholders | Oct 7, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Oct 7, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Oct 7, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Sep 18, 2024 | Meeting notice | SEC |
| 8-K · Current report | Aug 9, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 9, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jul 26, 2024 | Annual report | SEC |
| 8-K · Current report | Jul 24, 2024 | Current report | SEC |
| 10-K · Annual report | May 31, 2024 | Annual report | SEC |
| 424B4 · Prospectus | May 14, 2024 | Offer document | SEC |
| 8-K · Current report | May 13, 2024 | Material contract | SEC |
| 424B4 · Prospectus | May 10, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 3, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 3, 2024 | Other filings | SEC |
| 8-K · Current report | May 1, 2024 | Current report | SEC |
| S-1/A · Registration statement, amended | Apr 30, 2024 | Offer document | SEC |
| 8-K · Current report | Apr 23, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 17, 2024 | Other filings | SEC |
| S-1 · Registration statement | Apr 12, 2024 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 12, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 9, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Feb 8, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | Feb 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Feb 7, 2024 | Current report | SEC |
| CORRESP · Letter to the SEC | Feb 6, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 5, 2024 | Big-stake notice | SEC |
| UPLOAD · Letter from the SEC | Feb 2, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jan 26, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 28, 2023 | Financing | SEC |
| 424B5 · Prospectus | Dec 22, 2023 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Dec 1, 2023 | Offer document | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 15, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 3, 2023 | Management or board change | SEC |
| 8-K/A · Current report, amended | Sep 22, 2023 | Management or board change | SEC |
| ARS · Annual report to shareholders | Sep 13, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Sep 13, 2023 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Sep 13, 2023 | Meeting notice | SEC |
| 8-K · Current report | Sep 12, 2023 | Management or board change | SEC |
| 8-K · Current report | Sep 5, 2023 | Current report | SEC |
| 8-K · Current report | Aug 22, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 10, 2023 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jul 31, 2023 | Annual report | SEC |
| 8-K · Current report | Jul 24, 2023 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Jul 14, 2023 | Meeting notice | SEC |
| 10-K · Annual report | Jul 13, 2023 | Annual report | SEC |
| NT 10-K · Late filing notice | Jun 29, 2023 | Explanation request | SEC |
| 8-K · Current report | Mar 15, 2023 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 9, 2023 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 3, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| S-8 POS | Oct 25, 2022 | Offer document | SEC |
| S-8 POS | Oct 25, 2022 | Offer document | SEC |
| S-8 POS | Oct 25, 2022 | Offer document | SEC |
| S-8 POS | Oct 25, 2022 | Offer document | SEC |
| S-8 POS | Oct 25, 2022 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Oct 25, 2022 | Offer document | SEC |
| 4 · Change in ownership | Oct 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Oct 20, 2022 | Insider trade | SEC |
| 8-K · Current report | Oct 14, 2022 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Sep 22, 2022 | Meeting notice | SEC |
| DEFR14A | Sep 22, 2022 | Meeting notice | SEC |
| 8-K · Current report | Sep 6, 2022 | Current report | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Jul 26, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 26, 2022 | Meeting notice | SEC |
| 5 · Annual statement of ownership | Jul 8, 2022 | Insider trade | SEC |
| 10-K · Annual report | Jun 10, 2022 | Annual report | SEC |
| 4 · Change in ownership | Mar 10, 2022 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 10, 2022 | Insider trade | SEC |
| 8-K · Current report | Mar 10, 2022 | Management or board change | SEC |
| 8-K · Current report | Feb 28, 2022 | Material contract | SEC |
| 10-Q · Quarterly report | Feb 14, 2022 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2022 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 4, 2022 | Big-stake notice | SEC |
| 8-K · Current report | Nov 19, 2021 | Material contract | SEC |
| S-8 · Registration statement for employee plans | Nov 9, 2021 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 8, 2021 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Nov 1, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Oct 12, 2021 | Insider trade | SEC |
| 8-K · Current report | Oct 6, 2021 | Management or board change | SEC |
| 8-K · Current report | Oct 1, 2021 | Current report | SEC |
| DEFA14A · Additional proxy material | Sep 17, 2021 | Meeting notice | SEC |
| 8-K · Current report | Sep 17, 2021 | Current report | SEC |
| DEFA14A · Additional proxy material | Aug 30, 2021 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 19, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2021 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Aug 5, 2021 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Aug 5, 2021 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Jul 29, 2021 | Annual report | SEC |
| 10-K · Annual report | Jun 15, 2021 | Annual report | SEC |
| 8-K · Current report | May 13, 2021 | Management or board change | SEC |
| 8-K · Current report | Apr 19, 2021 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Mar 25, 2021 | Offer document | SEC |
Cap table
Built by 6ix from VivoSim Labs, Inc.’s releases · as of Nov 1, 2026
- Common shares
- 20,281,495
- Fully diluted
- 20,281,495
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 20,281,495 | Nov 1, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.85 · expire about Jul 2031 |
Share count over time
| Count | Shares |
|---|---|
| Nov 1, 2026 | 20,281,495 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Adam Stern Other companies: DarioHealth Corp. (Board Member · Since at least Mar 1, 2020); Cycurion, Inc. (Director · Jan 11, 2022 – Jan 11, 2022 · Past); Matinas BioPharma Holdings, Inc. (Director · May 16, 2019 – Aug 21, 2020 · Past) | Director · Since at least Jul 14, 2020 |
| Steven George Hughes Other companies: Atrium Therapeutics, Inc. (Chief Medical Officer · Since at least Feb 26, 2026); Avidity Biosciences, Inc (Chief Medical Officer · Since at least Jan 6, 2025); Arcturus Therapeutics Holdings Inc. (Chief Development Officer · Feb 18, 2020 – Dec 18, 2020 · Past) | Chief Medical Officer · Aug 1, 2018 – Aug 16, 2019 · Past |
| Tamar D Howson Other companies: Immunic, Inc. (Director · Since at least Oct 11, 2019); Cue Biopharma, Inc. (Director · Sep 17, 2020 – Jan 3, 2023 · Past); Lite Strategy, Inc. (Director · Jul 1, 2019 – Sep 29, 2023 · Past) | Director · Jul 26, 2018 – Jul 26, 2018 · Past |
| Keith Murphy Other companies: Matinas BioPharma Holdings, Inc. (Board Member · Since at least Mar 11, 2025); TuHURA Biosciences, Inc. (Director · Aug 19, 2020 – Sep 22, 2021 · Past) | Executive Chairman · Since at least Mar 13, 2012 |
| Chris Heberlig Other companies: Kiniksa Pharmaceuticals International, plc (EVP & CFO · May 23, 2018 – Sep 17, 2019 · Past) | President and CFO · Sep 15, 2020 – Sep 15, 2020 · Past |
| Norman Staskey Other companies: Azitra Inc (Chief Financial Officer · Since at least Jun 15, 2023) | Chief Financial Officer · Since at least Dec 30, 2024 |
| Richard Maroun Other companies: Whitehawk Therapeutics, Inc. (Director · Since at least Aug 26, 2021) | Director · Aug 17, 2016 – Sep 5, 2019 · Past |
| Sharon Collins Presnell Other companies: Viveve Medical, Inc. (Director · Oct 28, 2020 – Jan 3, 2023 · Past) | Chief Scientific Officer · Nov 16, 2017 – Nov 16, 2018 · Past |
| Alison Milhous | Director · Since at least Nov 17, 2023 |
| Amar Sethi | Chief Science Officer · Since at least Nov 24, 2025 |
All 17 people
| Person | Seat |
|---|---|
| Craig Kussman | Chief Financial Officer · Aug 22, 2016 – Aug 18, 2020 · Past |
| David Gobel | Director · Since at least Sep 15, 2020 |
| Doug Cohen | Chief Executive Officer · Since at least Nov 4, 2026 |
| Douglas Jay Cohen | Director · Since at least Jan 27, 2026 |
| Thomas E Jurgensen | General Counsel & Secretary · Mar 8, 2021 – Aug 31, 2022 · Past |
| Tony Lialin | Chief Commercial Officer · Since at least Aug 14, 2025 |
| Tony Serge Lialin | Chief Commercial Officer · Since at least Aug 31, 2026 |
Log in to ask 6ix AI your own questions about VivoSim Labs, Inc.